LEGN LEGEND BIOTECH CORP

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT.

Investors and other interested parties can access the live audio webcast through the  section of Legend’s website. The webcast replay will be available approximately 48 hours after the webcast.

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at and follow us on and .

INVESTOR CONTACT:

Jessie Yeung

Tel: (732) 956-8271

PRESS CONTACT:

Mary Ann Ondish

Tel: (914) 552-4625



EN
19/12/2024

Underlying

LEGNLEGEND BIOTECH CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LEGEND BIOTECH CORP

 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Reports First Quarter 2025 Results and Recent Highlight...

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI® labelAustralia’s TGA approved CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.0 billion, as of March 31, 2025, which Legend Biot...

19h / 57m 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Host Investor Conference Call on First Quarter 2025 ...

Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this . A replay of the webcast and...

April 29, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and R...

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CARVYKTI® at a Novartis production facilitySpain's national health system approved reimbursement for CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.1 billion, as of December 31, 2024, which Legend Biotech believes will provide financial run...

March 11, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Host Investor Conference Call on Fourth Quarter and ...

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 11, 2025, to review fourth-quarter and full-year 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s quarter and fiscal year performance. Investors and other interested parties may join the live audio webcast of the call ...

February 25, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Co...

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT. Investors and other interested parties can access the live audio webcast through the  section of Legend’s website. The webcast repl...

December 19, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch